Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ryan Ramaekers (NPI 1174539936)

Field	Value
Entity Type	Individual
Organization	Ryan Ramaekers
Address	2116 W Faidley Ave
City	Grand Island
State	NE
ZIP	68803
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	August 1, 2006

Payer Source	Total Paid
Medicare	$2.1M
Medicaid	$0

Key Findings

The provider’s Medicare revenue is highly concentrated in immunotherapy drugs and a single E/M code: J9271 (pembrolizumab) accounts for $1.1M and 53.2% of Medicare revenue, J9299 (nivolumab) accounts for $475.2K and 22.8%, and 99214 accounts for $145.6K and 7.0%; together the top three codes make up 82.9% of this provider's total Medicare revenue. This mix indicates the operation is centered on high-cost oncology infusions—particularly checkpoint inhibitor therapy—supported by office-based evaluation and management encounters rather than a broad, diversified set of services.

Business implications of the top codes point to an infusion-centered hematology/oncology practice: the dominance of J9271 and J9299 shows the practice primarily delivers immune checkpoint inhibitors, and the presence of chemotherapy administration codes such as 96413 ($46.6K) and add-on infusion codes (96417, 96415, 96411) confirms ongoing infusion workflows and staff/time resources for parenteral cancer therapies. This profile suggests revenue and operational dependence on drug-administered oncology care rather than procedure- or surgery-driven services.

Payer mix is effectively single-payer in operational terms: lifetime Medicare revenue is $2.1M while there is no Medicaid billing on file, so the provider’s public-payer exposure is concentrated in Medicare. This concentration implies limited state Medicaid throughput and sensitivity of overall revenue to Medicare reimbursement and utilization trends.

Competitive standing on the lead drug is notable but not dominant nationwide: for J9271 the provider ranks #209 of 1841 nationally (89th percentile; typical, unremarkable volume for this code), indicating a substantial pembrolizumab program that is above most peers but still within expected national volumes for oncology practices. In contrast, J9299 ranks #168 of 505 (67th percentile; typical, unremarkable volume for this code), positioning the provider as a moderate-volume nivolumab user relative to available national peers.

Evaluation-and-management activity is an outlier relative to national peers: 99214 ranks #2572 of 479517 (99th percentile; extreme outlier, far above typical national volume for this code), indicating unusually high E/M billing intensity for established outpatient encounters. Additional high-percentile E/M codes—99215 ($39.7K; rank #5294 of 145531, 96th percentile; notably above typical) and 99205 ($13.8K; rank #4228 of 66257, 93th percentile; notably above typical)—reinforce that the provider documents and bills a heavy volume of higher-complexity office visits.

The practice delivers a mix of oncology-specific supportive care and ancillary services alongside high-cost biologics: J0897 (denosumab) contributes $116.6K (5.6%), J1439 (ferric carboxymaltose) contributes $44.3K (2.1%), and lab/support items such as 36415 (1.3K claims, $10.1K) and 85025 (281 claims, $2.2K) appear in the top codes. This pattern is consistent with comprehensive cancer care that includes bone-modifying agents, iron replacement, blood draws, and routine monitoring embedded in an infusion practice.

Tenure data indicate an established clinician presence: the NPI was enumerated on 2006-08-01 (~20 years ago), suggesting long-term practice continuity that aligns with the cumulative Medicare revenue profile of $2.1M. Combined with the concentrated drug revenue, the longevity supports a sustained specialty focus rather than a recent shift into oncology infusion services.

Operational and risk considerations: because 82.9% of Medicare revenue is tied to three codes and there is no Medicaid volume, the provider’s revenue base is sensitive to shifts in utilization or reimbursement for pembrolizumab (J9271), nivolumab (J9299), and high-intensity E/M visits (99214). For network planning or contracting, payers and analysts should treat this entity as a Medicare-centric oncology infusion practice with concentrated drug exposure and above-typical office visit intensity.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

45 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	25,810	$40	$1.1M
J9299	Injection, nivolumab, 1 mg	19,800	$20	$475.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,670	$90	$145.6K
J0897	Injection, denosumab, 1 mg	6,480	$20	$116.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	500	$90	$46.6K
J1439	Injection, ferric carboxymaltose, 1 mg	44,250	$1	$44.3K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	320	$130	$39.7K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	140	$130	$18.4K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	90	$160	$13.8K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	210	$60	$11.9K

Showing 1–10 of 45

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Ryan Ramaekers — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

45 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	30	14,400	$40	$671.6K
J9299	5	10	19,300	$20	$444.5K
J0897	27	200	2,040	$20	$62.7K
J1439	5	30	25,880	$1	$26.4K
J9217	18	50	110	$130	$20.6K
96413	8	80	60	$90	$18.2K
99214	17	3,210	110	$70	$14.9K
J3490	26	30	60	$160	$11.3K
96401	13	30	120	$50	$11K
99213	696	3,220	90	$50	$7.9K

Showing 1–10 of 45

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ryan Ramaekers, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Winona Health Services	MN	General Acute Care Hospital	$0	$13.4M
St. Alexius Medical Center	ND	Specialist	$0	$3.6M
St. Alexius Medical Center	ND	General Acute Care Hospital	$0	$3.5M
Stefano Tarantolo	NE	Hematology & Oncology Physician	$3.2M	$0
Mid Dakota Clinic, Inc.	ND	Clinic/Center	$0	$2.9M
Samuel Mehr	NE	Nuclear Medicine Physician	$2.5M	$0
Ralph Hauke	NE	Hematology & Oncology Physician	$2.5M	$0
Gamini Sooriyaarachchi	FL	Medical Oncology Physician	$2.2M	$0
Joel Michalski	NE	Internal Medicine Physician	$2M	$0

Nearby Providers

Other providers in the same ZIP code as Ryan Ramaekers, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Go Physical Therapy, LLC	NE	Physical Therapist	$0	$12.4M
Saint Francis Medical Center	NE	General Acute Care Hospital	$0	$11M
Mid-plains Center For Behavioral Healthcare Services, Inc.	NE	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$10M
Grand Island Clinic Inc	NE	Family Medicine Physician	$0	$9.2M
Heartland Health Center, Inc.	NE	Federally Qualified Health Center (FQHC)	$0	$8.8M
Midwest Emergency Grand Island Inc	NE	Emergency Medicine Physician	$0	$3.8M
Active Family Chiropractic And Acupuncture PC	NE	Chiropractor	$0	$3.8M
Twin Rivers Urgent Care LLC	NE	Family Medicine Physician	$0	$2.9M
Family Practice Of Grand Island P C	NE	Family Medicine Physician	$0	$2.2M
Wholeness Healing Center PC	NE	Mental Health Counselor	$0	$2.1M

Ryan Ramaekers — Billing Profile & Reimbursement Data

Sign up for Ryan Ramaekers — Billing Profile & Reimbursement Data policy alerts

Ryan Ramaekers — Billing Profile & Reimbursement Data

Sign up for Ryan Ramaekers — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References